Atreca Inc BCEL

Alternate Symbol(s): COLUF

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.

PINL:BCEL - Post by User

Atreca Inc

Bullboard Posts

Post by TheHoboon Apr 07, 2010 12:11pm

416 Views

Post# 16965349

CSI L2 @ 12:11pm Eastern

Orders/Shares

Price

Shares/Orders

3 / 2100	7.45	7.46	500 / 3
4 / 1900	7.44	7.47	200 / 2
1 / 1000	7.43	7.48	1400 / 1
2 / 3500	7.42	7.49	1000 / 1
1 / 700	7.41	7.5	10700 / 6
2 / 2900	7.4	7.51	1800 / 3
1 / 1200	7.39	7.53	3400 / 5
1 / 1000	7.37	7.54	2500 / 2
1 / 1800	7.36	7.55	13700 / 5
2 / 1700	7.35	7.57	2000 / 1
2 / 1500	7.32	7.59	1600 / 1
1 / 300	7.31	7.6	6000 / 5
3 / 4100	7.3	7.62	200 / 1
1 / 500	7.28	7.65	1000 / 1
2 / 1600	7.26	7.7	9200 / 2
2 / 2000	7.25	7.75	15500 / 5
1 / 300	7.22	7.77	2000 / 1
3 / 4000	7.2	7.8	500 / 1
1 / 1000	7.16	7.86	500 / 1
2 / 1500	7.15	7.87	2000 / 1